Akebia Therapeutics AKBA
NASDAQ AKBA
$0.57 +0.03 (+5.89%)
At close: Nov 11, 2026 · 4:00 PM EST

Akebia Therapeutics (AKBA) Gains from Sales and Divestitures (2025)

Updated

Akebia Therapeutics (AKBA) posted Gains from Sales and Divestitures of $172,000 for FY2025.

Analysis

Akebia Therapeutics (AKBA) Gains from Sales and Divestitures (2025) Analysis & Trends

  • The FY2025 figure stands as the lowest annual Gains from Sales and Divestitures since FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Akebia Therapeutics 149.86 Mn -512.48 Mn 30.54 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 172,000.00
API Access

Akebia Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=AKBA&period=max&api_key=YOUR_API_KEY